Breast Implant-Associated Anaplastic Large Cell Lymphoma

Facts relating to Breast Implant-associated anaplastic Cell lymphoma

According to the U.S. Food and Drug Administration (FDA), as of September 2020 more than 700 people worldwide have been diagnosed with breast implant-associated anaplastic large cell lymphoma (BIA-ALCL).

The FDA classifies BIA-ALCL as an uncommon cancer. The organization believes that women with textured breast implants have a small but increased risk of developing this disease in the tissue capsule the body forms around a textured implant over time. ALCL may also be found in the lymph nodes and the skin.

At this time, data indicates that the incidence of ALCL is low, even among breast implant patients. Between one in 355 to one in 2,200 of these individuals develop the disease depending on type of textured implant, according to recent studies. Currently, there does not seem to be a greater cancer risk based on the type of implant (silicone or saline) or the type of surgery (breast augmentation or reconstruction).

About Lymphoma related to Breast implant:

Overall, lymphomas of any type that occur in the breast are rare, accounting for only 1% to 2% of all non-Hodgkin lymphomas. Most breast lymphomas involve B cells. However, in BIA-ALCL the diseased cells are T cells. While they play different roles, both are cells of the immune system.

Putting your trust in us:

You can be sure you are being cared for by renowned physicians with the highest levels of experience and skill at ACH.